DOOR/RADAR: A Gateway into the Unknown?

Clinical Infectious Diseases

Volumn 62, Issue 6, 2015, Pages 814-815

  Phillips, Patrick Peter John ^a   Morris, Tim Peter ^a,b   Walker, Ann Sarah ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; RIFAPENTINE; ANTIINFECTIVE AGENT;

ALTERNATIVE HYPOTHESIS; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL (TOPIC); DESIRABILITY OF OUTCOME RANKING; HEALTH CARE; HUMAN; INTENTION TO TREAT ANALYSIS; LETTER; PRIORITY JOURNAL; PROBABILITY; RESPONSE ADJUSTED FOR DURATION OF ANTIBIOTIC RISK; SAMPLE SIZE; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; METHODOLOGY;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; HUMANS; RESEARCH DESIGN;

EID: 84960078503     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ1002     Document Type: Letter

References (4)

1. Evans SR, Rubin D, Follmann D, et al. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clin Infect Dis 2015:civ495.
2. Center for Disease Dynamics Economics and Policy (CDDEP). The State of the World's Antibiotics, 2015: Executive Summary. 2015. Available at: http://www.cddep.org/publications/state-worlds-antibiotics-2015-executive-summary. Accessed 17 October 2015.
3. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371:1599-608.
4. Gillespie SH, Crook AM, McHugh TD, et al. Fourmonth moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371:1577-87.